Mel Mann shares his inspiring 30-year journey with chronic myeloid leukemia, from a terminal diagnosis to long-term survival.

Kolibaba, KS, Druker BJ. Current Status of Treatment for Chronic Myelogenous Leukemia. MedGenMed 2(2), 2000 [formerly published in Medscape Hematology-Oncology eJournal 3(2), 2000]. Available at ...

Opens in a new tab or window The rare hematologic malignancy known as chronic myelomonocytic leukemia ... in CML are unclear. A new study found that mutations in activated signaling and myeloid ...

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...

Chronic myeloid leukemia (CML) starts in the myeloid cells in the ... Depending on the type of leukemia, early diagnosis and treatment are important for a better prognosis and more varied ...

80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) -- ... Tumor-Induced B Cell Changes Reveal Potential Biomarker for Treatment Response ...

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...

The pharma company now has two positive proof-of-concept trials under its belt, including its weight-loss pill.

Updated 96-week data from the ASC4FIRST trial show asciminib significantly outperforms standard TKIs in major molecular ...

People with APL respond better to treatment than people with other types of AML ... acute leukemia than people without this exposure. Having certain blood conditions. Chronic myeloproliferative ...

(IN BRIEF) Novartis has announced promising 96-week results from the Phase III ASC4FIRST trial, showcasing Scemblix® (asciminib) as a superior treatment for newly diagnosed Philadelphia ...